Evidence map›Paper›PMID 37508333›Full record

ArticleBiology2023

Sample Treatment with Trypsin for RT-LAMP COVID-19 Diagnosis.

Soraya García-Sorribes, Francisco Lara-Hernández, Iris Manzano-Blasco, Jessica Abadía-Otero, Eliseo Albert, Alba Mulet, Laisa Socorro Briongos-Figuero, Miriam Gabella-Martín, Ignacio Torres, Jaime Signes-Costa and 4 more

Open access · goldAbstract read
In one paragraph

Article in Biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Standardization and performance of SARS-CoV-2 RT-LAMP detection: a reliable, inexpensive, and alternative diagnostic assay.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Soraya García-SorribesGenomic and Diabetes Unit, INCLIVA Biomedical Research Institute, 46010 Valencia, Spain.ORCID 0000-0002-0112-1344
Francisco Lara-HernándezGenomic and Diabetes Unit, INCLIVA Biomedical Research Institute, 46010 Valencia, Spain.ORCID 0000-0002-5167-035X
Iris Manzano-BlascoGenomic and Diabetes Unit, INCLIVA Biomedical Research Institute, 46010 Valencia, Spain.ORCID 0000-0003-2313-918X
Jessica Abadía-OteroInternal Medicine Service, Rio Hortega University Hospital, 47012 Valladolid, Spain.
Eliseo AlbertMicrobiology Service, University Clinic Hospital, INCLIVA, 46010 Valencia, Spain.
Alba MuletPulmonary Department, University Clinic Hospital, INCLIVA, 46010 Valencia, Spain.
Laisa Socorro Briongos-FigueroInternal Medicine Service, Rio Hortega University Hospital, 47012 Valladolid, Spain.ORCID 0000-0003-3709-818X
Miriam Gabella-MartínInternal Medicine Service, Rio Hortega University Hospital, 47012 Valladolid, Spain.
Ignacio TorresMicrobiology Service, University Clinic Hospital, INCLIVA, 46010 Valencia, Spain.
Jaime Signes-CostaPulmonary Department, University Clinic Hospital, INCLIVA, 46010 Valencia, Spain.
David NavarroMicrobiology Service, University Clinic Hospital, INCLIVA, 46010 Valencia, Spain.
Juan-Carlos Martín-EscuderoInternal Medicine Service, Rio Hortega University Hospital, 47012 Valladolid, Spain.
Ana-Bárbara García-GarcíaGenomic and Diabetes Unit, INCLIVA Biomedical Research Institute, 46010 Valencia, Spain.ORCID 0000-0002-2162-6606
Felipe Javier ChavesGenomic and Diabetes Unit, INCLIVA Biomedical Research Institute, 46010 Valencia, Spain.ORCID 0000-0001-8009-3689
INCLIVA Health Research Institute · ESHospital Universitario Río Hortega · ESInstituto de Salud Carlos III · ESUniversidad de Valladolid · ES

Funding

Generalitat Valenciana FDEGENT/2019/006Instituto de Salud Carlos III CIBER (CB07/08/18)Instituto de Salud Carlos III COV20_00279Instituto de Salud Carlos III PI21/00506
6 · The paper itself

Abstract

The SARS-CoV-2 coronavirus is responsible for the COVID-19 pandemic resulting in a global health emergency. Given its rapid spread and high number of infected individuals, a diagnostic tool for a rapid, simple, and cost-effective detection was essential. In this work, we developed a COVID-19 diagnostic test, that incorporates a human internal control, based on the Reverse Transcription Loop-Mediated Isothermal Amplification (RT-LAMP). When working with synthetic SARS-CoV-2 RNA, the optimized RT-LAMP assay has a sensitivity of 10 viral copies and can be detected by fluorescence in less than 15 min or by the naked eye in 25 min using colorimetric RT-LAMP. To avoid the RNA extraction step, a pre-treatment of the sample was optimized. Subsequently, a validation was performed on 268 trypsin treated samples (including nasopharyngeal, buccal, and nasal exudates) and amplified with colorimetric RT-LAMP to evaluate its sensitivity and specificity in comparison with RT-qPCR of extracted samples. The validation results showed a sensitivity and specificity of 100% for samples with Ct ≤ 30. The rapid, simple, and inexpensive RT-LAMP SARS-CoV-2 extraction-free procedure developed may be an alternative test that could be applied for the detection of SARS-CoV-2 or adapted to detect other viruses present in saliva or nasopharyngeal samples with higher sensitivity and specificity of the antibody test.

Indexed as

colorimetryCOVID-19RNA extraction-freeRT-LAMPSARS-CoV-2trypsin

Identifiers

PMID37508333
PMCPMC10376771
OpenAlexW4382237973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.